Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nitto Denko, a Japan-based diversified materials manufacturer, has acquired Avecia Biotechnology, through its New Jersey-based wholly owned subsidiary Nitto Americas.
Subscribe to our email newsletter
Besides cGMP (current good manufacturing practices) manufacturing, Avecia Biotechnology ‘s services also include the development of analytical methods, process validation, stability studies, quality control, and regulatory support for DNA and RNA based therapeutics.
The acquisition is expected to further boost Nitto Denko’s business base, which is active in nucleic acid drug technology with its wholly owned subsidiary Nitto Denko Technical Corporation.
Nitto Denko intends to leverage complementary market positions and client relationships; combined IP and technologies, including drug delivery technologies; and nucleic acid manufacturing efficiencies and cost of goods with its proprietary solid polymer support technology.
Nitto Denko also plans to leverage Avecia Biotechnology’s prime location and expansion possibilities to grow the service offering for the benefit of its clients.